Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

Original reporting
Published Nov 11, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA — source image
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

The company provided detailed guidance on HMB002 efficacy and upcoming trial designs, which are new disclosures not previously reported.

02

Market read

First public disclosure of trial guidance and upcoming data dates, offering traders a fresh catalyst for COAG.

03

What to watch

Regulatory timeline uncertainties and competition from other von Willebrand disease programs could temper upside.

Relevance 7/10Novelty 7/10Timing: pre-February 2027 data release

Background

Hemab Therapeutics (COAG) is a clinical‑stage biotech focused on rare bleeding disorders, presenting its Q3 2026 earnings call highlights.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

Hemab Therapeutics disclosed Phase I/II trial guidance and upcoming SOLARA Phase III data, including expected >50% bleed reduction and dosing details.

Expected impact

likely upward pressure as market prices in potential efficacy success

Evidence & confidence

Guidance of >50% bleed reduction and detailed dosing signals strong clinical progress, which typically lifts biotech stocks before data release.

Market effects

May lift other rare‑bleeding disorder biotech peers as investors reassess pipeline potential.

Limited to US biotech sector; no broader regional effect.

Modest global relevance, primarily affecting niche hematology investors.

Counterpoint

If trial data fall short of >50% reduction, the stock could face sharp downside.

Key entities

  • Hemab Therapeutics Holdings Inc

    US‑listed biotech developing HMB002 for von Willebrand disease.

  • CEO Benny Sorensen

    Provided forward‑looking statements on trial data and regulatory expectations.

Related articles

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A

$COAGMedAI 8/10

Hemab Begins Pivotal Study Of Potential Preventive Treatment For Glanzmann Thrombasthenia

Hemab Therapeutics (COAG) initiated a Phase 3 trial (SOLARA) for sutacimig, a potential preventive treatment for Glanzmann thrombasthenia (GT). The study aims to enroll 75 participants, with primary endpoint comparing treated bleed rates during treatment vs. run-in period. Sutacimig has received Fast Track, Orphan Drug, and Breakthrough Therapy designations from the FDA. COAG stock is currently trading at $46.30, down 5.55%.